Finance
Finance
HomeALKS • NASDAQ
Alkermes Plc
$26.55
After Hours:
$26.55
(0.00%)0.00
Closed: Aug 6, 4:30:00 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$26.60
Day range
$26.10 - $26.65
Year range
$25.56 - $36.45
Market cap
4.38B USD
Avg Volume
2.08M
P/E ratio
12.73
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Jun 2025Y/Y change
Revenue
390.66M-2.12%
Operating expense
248.22M8.98%
Net income
87.10M-4.66%
Net profit margin
22.30-2.58%
Earnings per share
0.68-3.04%
EBITDA
100.80M-13.51%
Effective tax rate
16.92%
Total assets
Total liabilities
(USD)Jun 2025Y/Y change
Cash and short-term investments
1.02B15.94%
Total assets
2.25B2.08%
Total liabilities
628.22M-31.92%
Total equity
1.62B
Shares outstanding
165.08M
Price to book
2.70
Return on assets
10.72%
Return on capital
14.16%
Net change in cash
(USD)Jun 2025Y/Y change
Net income
87.10M-4.66%
Cash from operations
150.20M2.86%
Cash from investing
-29.21M-156.34%
Cash from financing
405.00K100.49%
Net change in cash
121.39M6.12%
Free cash flow
115.42M-42.08%
About
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
Founded
1987
Employees
1,800
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu